Literature DB >> 10676978

Cumulative experience with Haemophilus ducreyi 35000 in the human model of experimental infection.

J A Al-Tawfiq1, J Harezlak, B P Katz, S M Spinola.   

Abstract

BACKGROUND AND OBJECTIVES: To study Haemophilus ducreyi pathogenesis, the authors developed an experimental model of infection in human volunteers. The authors analyze their cumulative experience with strain 35000 in the model and calculate the papule and pustule formation rates for estimated delivered doses (EDDs) ranging from 1 cfu to 100 cfu. STUDY
DESIGN: Sixty-five volunteers were included in the analysis. A total of 139 sites were available for calculation of the papule formation rate, and 117 sites were available for calculation of the pustule formation rates.
RESULTS: The effect of EDDs and probabilities of papule formation and the pustule formation were dose-dependent. Increasing the EDD resulted in a higher probability of papule and pustule formation.
CONCLUSION: H ducreyi is highly infectious for humans. Inoculation of an EDD of 1 cfu causes a papule formation rate of 50%. Pustule formation rates are approximately 50% for 27 cfu and 90% for 100 cfu.

Entities:  

Mesh:

Year:  2000        PMID: 10676978     DOI: 10.1097/00007435-200002000-00009

Source DB:  PubMed          Journal:  Sex Transm Dis        ISSN: 0148-5717            Impact factor:   2.830


  19 in total

1.  Transcription of candidate virulence genes of Haemophilus ducreyi during infection of human volunteers.

Authors:  R E Throm; S M Spinola
Journal:  Infect Immun       Date:  2001-03       Impact factor: 3.441

Review 2.  Immunopathogenesis of Haemophilus ducreyi infection (chancroid).

Authors:  Stanley M Spinola; Margaret E Bauer; Robert S Munson
Journal:  Infect Immun       Date:  2002-04       Impact factor: 3.441

3.  Differences in host susceptibility to disease progression in the human challenge model of Haemophilus ducreyi infection.

Authors:  Stanley M Spinola; Cliffton T H Bong; Andrew L Faber; Kate R Fortney; Stacy L Bennett; Carisa A Townsend; Beth E Zwickl; Steven D Billings; Tricia L Humphreys; Margaret E Bauer; Barry P Katz
Journal:  Infect Immun       Date:  2003-11       Impact factor: 3.441

4.  Cloning, overexpression, purification, and immunobiology of an 85-kilodalton outer membrane protein from Haemophilus ducreyi.

Authors:  K L Thomas; I Leduc; B Olsen; C E Thomas; D W Cameron; C Elkins
Journal:  Infect Immun       Date:  2001-07       Impact factor: 3.441

5.  Permeases of the sap transporter are required for cathelicidin resistance and virulence of Haemophilus ducreyi in humans.

Authors:  Sherri D Rinker; Xiaoping Gu; Kate R Fortney; Beth W Zwickl; Barry P Katz; Diane M Janowicz; Stanley M Spinola; Margaret E Bauer
Journal:  J Infect Dis       Date:  2012-08-28       Impact factor: 5.226

6.  Expression of sialylated or paragloboside-like lipooligosaccharides are not required for pustule formation by Haemophilus ducreyi in human volunteers.

Authors:  R S Young; K Fortney; J C Haley; A F Hood; A A Campagnari; J Wang; J A Bozue; R S Munson; S M Spinola
Journal:  Infect Immun       Date:  1999-12       Impact factor: 3.441

7.  Expression of the LspA1 and LspA2 proteins by Haemophilus ducreyi is required for virulence in human volunteers.

Authors:  Diane M Janowicz; Kate R Fortney; Barry P Katz; Jo L Latimer; Kaiping Deng; Eric J Hansen; Stanley M Spinola
Journal:  Infect Immun       Date:  2004-08       Impact factor: 3.441

8.  Haemophilus ducreyi requires an intact flp gene cluster for virulence in humans.

Authors:  Stanley M Spinola; Kate R Fortney; Barry P Katz; Jo L Latimer; Jason R Mock; Merja Vakevainen; Eric J Hansen
Journal:  Infect Immun       Date:  2003-12       Impact factor: 3.441

9.  Development of a rapid immunodiagnostic test for Haemophilus ducreyi.

Authors:  Kristine Patterson; Bonnie Olsen; Christopher Thomas; Dora Norn; Milton Tam; Christopher Elkins
Journal:  J Clin Microbiol       Date:  2002-10       Impact factor: 5.948

10.  Experimental infection of human volunteers with Haemophilus ducreyi: fifteen years of clinical data and experience.

Authors:  Diane M Janowicz; Susan Ofner; Barry P Katz; Stanley M Spinola
Journal:  J Infect Dis       Date:  2009-06-01       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.